Health Reform and the Substance Use Disorder Treatment System: A Time of Change

Journal of Psychoactive Drugs

Volumn 49, Issue 2, 2017, Pages 91-94

  Clark, H Westley ^a  

^a SANTA CLARA UNIVERSITY   (United States)

Author keywords

Health reform; substance use disorder treatment

Indexed keywords

CARFENTANIL; DIAMORPHINE; FENTANYL; OPIATE;

DEATH; DRUG DEPENDENCE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HOSPITAL ADMISSION; HUMAN; INTOXICATION; PRESCRIPTION; REVIEW;

HEALTH CARE REFORM; HUMANS; PATIENT PROTECTION AND AFFORDABLE CARE ACT; SUBSTANCE-RELATED DISORDERS;

EID: 85020240419     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2017.1315471     Document Type: Review

References (11)

1. Aletraris, L., M. B., Edmond, and P. M., Roman. 2017. Insurance receipt and readiness for opportunities under the Affordable Care Act:A national survey of treatment providers for substance use disorders. Journal of Psychoactive Drugs 49 (2):141–50. doi:10.1080/02791072.2017.1306661
2. Aletraris, L., P. M., Roman, and J., Pruett. 2017. Integration of care in the implementation of the Affordable Care Act:Changes in treatment services in a national sample of centers treating substance use disorders. Journal of Psychoactive Drugs 49 (2):132–40. doi:10.1080/02791072.2017.1299263.
3. Danovitch, I., and D., Kan. 2017. The addiction benefits scorecard:A framework to promote health insurer accountability and support consumer engagement. Journal of Psychoactive Drugs 49 (2):122–31. doi:10.1080/02791072.2017.1296210.
4. Frank, R. G., and H. A., Pollack. 2017. Addressing the fentanyl threat to public health. New England Journal of Medicine 376 (7):605–07. doi:10.1056/NEJMp1615145.
5. Healthcare.gov. n.d. The “metal” categories:Bronze, silver, gold & platinum. https://www.healthcare.gov/search/?q=metal%20plans (accessed April 15, 2017).
6. Knudsen, H. K., M. R., Lofwall, J. R., Havens, and S. L., Walsh. 2015. States’ implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Drug and Alcohol Dependence 157:36–43. doi:10.1016/j.drugalcdep.2015.09.032.
7. Knudsen, H. K., and J. L., Studts. 2017. Perceived impacts of the Affordable Care Act:Perspectives of buprenorphine prescribers. Journal of Psychoactive Drugs 49 (2):111–21. doi:10.1080/02791072.2017.1295335.
8. Quinn, A. E., M. T., Stewart, M., Brolin, C., Horgan, and N. E., Lane. 2017. Massachusetts substance use disorder treatment organizations’ perspectives on the Affordable Care Act:Changes in payment, services, and system design. Journal of Psychoactive Drugs 49 (2):151–59. doi:10.1080/02791072.2017.1301600.
9. Substance Abuse and Mental Health Services Administration (SAMHSA). n.d. National Survey on Drug Use and Health, 2014 and 2015 (Table 1.23A). Center for Behavioral Health Statistics and Quality. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.pdf (accessed May 2, 2017).
10. Smith, D. E., 2017. Medicalizing the opioid epidemic in the U.S. in the era of health care reform. Journal of Psychoactive Drugs 49 (2):95–101. doi:10.1080/02791072.1983.10472116.
11. The White, House. 2017. Presidential executive order establishing the President's Commission on Combating Drug Addiction and The Opioid Crisis. https://www.whitehouse.gov/the-press-office/2017/03/30/presidential-executive-order-establishing-presidents-commission (accessed May 2, 2017).